{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:40Z","timestamp":1789764280918,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.omtm.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T07:09:53Z","timestamp":1552720193000},"page":"334-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models"],"prefix":"10.1016","volume":"13","author":[{"given":"Elisabeth A.","family":"Spronck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Vall\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander J.","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.03.002_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1389450053344975","article-title":"Huntington\u2019s disease: new frontiers for molecular and cell therapy","volume":"6","author":"Melone","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omtm.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtm.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","article-title":"Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing","volume":"29","author":"Aronin","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtm.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","article-title":"Delivering a disease-modifying treatment for Huntington\u2019s disease","volume":"20","author":"Godinho","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtm.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"e0175968","DOI":"10.1371\/journal.pone.0175968","article-title":"Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111\/+ mouse model of Huntington\u2019s disease","volume":"12","author":"Coffey","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/nat.2018.0720","article-title":"Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients","volume":"28","author":"van Roon-Mom","year":"2018","journal-title":"Nucleic Acid Ther."},{"issue":"R1","key":"10.1016\/j.omtm.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1093\/hmg\/ddr137","article-title":"RNAi medicine for the brain: progresses and challenges","volume":"20","author":"Boudreau","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In\u00a0vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtm.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2009.286","article-title":"Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain","volume":"18","author":"Markakis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","article-title":"The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies","volume":"2","author":"Li","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.omtm.2019.03.002_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington\u2019s Disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington\u2019s Disease Minipig Model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.03.002_bib20","doi-asserted-by":"crossref","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington\u2019s disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.03.002_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2019.03.002_bib22","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/hmg\/ddw212","article-title":"An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes","volume":"25","author":"Southwell","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","article-title":"Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials","volume":"1792","author":"Ferrante","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtm.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/hmg\/8.1.115","article-title":"Length-dependent gametic CAG repeat instability in the Huntington\u2019s disease knock-in mouse","volume":"8","author":"Wheeler","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington\u2019s disease CAG expansion","volume":"17","author":"White","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib26","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1073\/pnas.1524575113","article-title":"Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib28","first-page":"4920","article-title":"A small molecule p75NTR ligand normalizes signalling and reduces Huntington\u2019s disease phenotypes in R6\/2 and BACHD mice","volume":"25","author":"Simmons","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2019.03.002_bib29","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.03.002_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.stemcr.2017.11.005","article-title":"Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6\/2 and Q140 Huntington\u2019s Disease Mice","volume":"10","author":"Reidling","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.omtm.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fneur.2017.00516","article-title":"Chronic 5-Aminoimidazole-4-Carboxamide-1-\u03b2-d-Ribofuranoside Treatment Induces Phenotypic Changes in Skeletal Muscle, but Does Not Improve Disease Outcomes in the R6\/2 Mouse Model of Huntington\u2019s Disease","volume":"8","author":"Par\u00e9","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtm.2019.03.002_bib32","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-017-04990-1","article-title":"Laquinimod treatment in the R6\/2 mouse model","volume":"7","author":"Ellrichmann","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2019.03.002_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.stemcr.2016.08.018","article-title":"ESC-Derived BDNF-Overexpressing Neural Progenitors Differentially Promote Recovery in Huntington\u2019s Disease Models by Enhanced Striatal Differentiation","volume":"7","author":"Zimmermann","year":"2016","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.omtm.2019.03.002_bib34","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.03.002_bib35","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J.\u00a0Neurosci."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:27:17Z","timestamp":1762421237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119300294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":35,"alternative-id":["S2329050119300294"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.03.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}